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Abstract
Objective: Our objective was to estimate primary resistance in an urban setting in a developing country characterized by high
antiretroviral (ARV) coverage over the diagnosed population and also by an important proportion of undiagnosed individuals,
in order to determine whether any change in primary resistance occurred in the past five years.
Design: We carried out a multi-site resistance surveillance study according to WHO HIV resistance guidelines, using a weighted
sampling technique based on annual HIV case reports per site.
Methods: Blood samples were collected from 197 drug-naive HIV-1-infected individuals diagnosed between March 2010 and
August 2011 at 20 HIV voluntary counselling and testing centres in Buenos Aires. Clinical records of enrolled patients at the time
of diagnosis were compiled. Viral load and CD4 counts were performed on all samples. The pol gene was sequenced and the
resistance profile determined. Phylogenetic analysis was performed by neighbour-joining (NJ) trees and bootscanning analysis.
Results: We found that 12 (7.9%) of the 152 successfully sequenced samples harboured primary resistance mutations, of which
K103N and G190A were the most prevalent. Non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance mutations were
largely the most prevalent (5.9%), accounting for 75% of all primary resistance and exhibiting a significant increase (p0.0072)
in prevalence during the past 10 years as compared to our previous study performed in 19972000 and in 20032005.
Nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor primary resistance were low and similar to the one
previously reported.
Conclusions: Levels of primary NNRTI resistance in Buenos Aires appear to be increasing in the context of a sustained ARV
coverage and a high proportion of undiagnosed HIV-positive individuals.
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Introduction
Highly active antiretroviral therapy (HAART) can increase life
expectancy of HIV-positive patients [14] and prevent
transmission [5]. However, it may also drive the selection
of mutations that confer resistance to antiretroviral (ARV)
drugs in patients under treatment. Transmission of drug-
resistant variants constitutes a public health issue since it can
contribute to failure of first-line ARV treatment [6]. Pre-
valence of primary resistance appears to be correlated with
treatment coverage, being higher in developed settings
[719]. In fact, international guidelines recommend perform-
ing genotypic resistance testing in all drug-naı¨ve patients,
before beginning a first-line ARV regimen [2022].
Although by the end of the 1990s, improvements in ARV
regimens had limited the rate of selection and transmission
of resistance mutations (mainly for those associated with
nucleoside reverse transcriptase inhibitor (NRTI) resistance),
significant increasing trends in primary resistance have
been reported in the past decade in settings where HAART
regimens are broadly implemented: increasing trends appear
to be observed exclusively in developed settings, such as the
United Kingdom [23], Germany [24] and the United States
[25], but not in developing settings [2628]. This might be
associated with the fact that the high proportion of
undiagnosed individuals in developing countries may limit
population-level selective forces driven by ARV treatment. It
is not clear whether the low prevalence of primary resistance
in these settings will remain stable or will increase at a
slower rate than that of the developed settings.
Argentina is a developing country with approximately
130,000 individuals living with HIV, with half of them unaware
of their infection [29]. Free access to ARV drugs has been
guaranteed since 1992, and Argentina, together with Brazil,
was the first Latin American countries that established an ART
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delivery programme. Buenos Aires, the capital city, is the most
populated, containing 47.1% of reported HIV cases between
2001 and 2010 [30]. In Buenos Aires, there are 11,124 people
receiving ARV treatment with 67% of them taking NRTI drugs:
40% (4442) receive AZT/3TC, 13% (1434) ABC/3TC, 11% (1250)
TDF/FTC and 3% (305) TDF/3TC. A 52% (5738) receive NNTRI
drugs, 40% (4435) efavirenz and 12% (1303) with nevirapine,
and 38% (4232) take at least one protease inhibitor, of which
454 are not reinforced with ritonavir.
In the setting of Buenos Aires city, we have previously
reported a prevalence of primary resistance among newly
diagnosed individuals of 2.3% (CI: 05.5, n86) in 1997
2000 [31] and 4.2% (CI: 1.96.5, n284) in 20032005 [32].
In addition, a prevalence of 7.7% (CI: 0.414.9, n52) was
reported for individuals recently infected in 20042005 [33].
Importantly, non-nucleoside reverse transcriptase inhibitors
(NNRTI) resistance mutations (mainly K103N) were not found
in the first study but were detected in the last two studies.
In the present report, we study individuals recently diag-
nosed between 2010 and 2011 and show that the increasing
trend in overall primary resistance persists driven mainly by
the accumulation of NNRTI-associated resistance mutations.
Materials and methods
Study design
This resistance surveillance study was designed according to
WHO HIV resistance guidelines [34]. These guidelines do not
make restrictions in age as the 2008 updated guidelines do.
This allows us to compare our results with our previous
studies and also to reach a higher sample size. A comparison
with results obtained following the 2008 updated guidelines
is provided in this article. In brief, using a cross-sectional
weighted sampling technique, newly HIV-diagnosed indivi-
duals were sequentially selected at the time of diagnosis at 20
health centres that include voluntary and counselling testing
sites (VCTs) and infectious diseases services from public
hospitals and private clinics. The proportion of individuals
included from each site reflected the proportion of new cases
reported to the Ministry of Health from 2003 to 2009.
Study population
The inclusion criteria were being HIV positive, age older than
18, with first confirmed diagnosis of HIV infection within
a period of 180 days before study entry, with confirmed
unexposure to ARV therapy and agreement to participate in
the study by signing an informed consent. A total of 197
drug-naı¨ve newly diagnosed HIV-1 individuals were enrolled
between March 2010 and August 2011, and those who met
the inclusion criteria were included in the study. The final
study population (N152) comprised 116 men, 33 women
and 3 transsexual, of whom 28 (18%) were younger than
25 years, with an overall average age of 37 years.
Ethical approval and details of the consent procedure
for the study
The project was initially submitted to the Bioethics Committee
of the Mun˜iz Hospital specialized in infectious diseases in
Buenos Aires, Argentina. It is a UNESCO-recognized committee
and is listed among the ethics institutions list available at
http://www.unesco.org/new/en/social-and-human-sciences/
themes/global-ethics-observatory/access-geobs/.The Bioethics
Committee of the Mun˜iz Hospital approved the project on
16 November 2009. The project was later validated by the
Academic and Scientific Direction of the Government of the
City of Buenos Aires on 29 September 2010. Patients were
asked to read and, if agree with participating in the study, to
sign an informed consent form. In this form, the patient can
read in an accessible language the objectives of the project
and the assays to be performed over the collected samples.
HIV-1 RNA isolation and sequencing
RNA was isolated from plasma by the QIAamp viral extraction
Kit (QIAGEN GmbH, Hilden, Germany). The pol gene was
amplified between positions 2142 and 3798 (reference strain
HXB2 numbering [35]) by reverse transcriptase-polymerase
chain reaction (RT-PCR) and was sequenced by ABI Prism
3100/3100-Avant equipment (Applied Biosystems, Foster
City, CA, USA).
For pol gene amplification, outer primers 5CP1 (5?-GAA
GGGCACACAGCCAGAAATTGCAGGG-3?) and RT3.1 (5?-GCTCCT
ACTATGGGTTCTTTCTCTAACTGG-3?), and inner primers 1F (5?-
CAGACCAGAGCCAACAGCCCC-3?), A35 (5?-ATTGGTTGCACTTT
AAATTTTCCCATTAGCCCTATT-3?), 6B (5?-CATTGTTTAACTTTTGG
GCC-3?), RT3208F (5?-AACATCAGAAAGAACCTCCATT-3?), NE1
(5?-CGACCTGACAGTTACTGTATGTCTTCAATCACC-3?) and 6B
(5?-CATTGTTTAACTTTTGGGCCATCCATTCCTGGC-3?) were used.
The reverse transcription reaction was performed by
heating at 428C for 50 minutes and 708C for 15 minutes
using the Superscript II RT enzyme and the RT3.1 primer. Pol
gene amplification was performed by nested PCR using the
primers listed above. The PCR conditions were 3 first minutes
at 958C, then 5 cycles of 15 seconds of denaturation at 958C,
15 seconds of primer annealing at 568C and 1:40 minutes of
elongation at 728C. And at the end of 30 cycles: 15 seconds
of denaturation at 908C, 15 seconds of primer anneal at 568C
and 1:40 minutes of elongation at 728C. A final elongation
was performed for 10 minutes at 728C.
Viral load and CD4 testing
Plasma viral load (VL) was assessed by branched DNA
(b-DNA) technology (Versant HIV-1 RNA 3.0; Bayer Co.,
Tarrytown, NY) with a detection limit of 50 HIV-1 RNA
copies/ml. CD4cells from peripheral blood were measured
by cytometry (Coulter XL; Coulter Co., Hialeah, FL, USA).
Resistance analysis
Sequences were analyzed to identify mutations associated
with reduced susceptibility to protease and RT inhibitors, as
reported by the International AIDS Society-USA in 2010 [36]:
RTM41L, A62V, K65R, D67N, 69 insert, K70R, L74V, V75I,
F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F,
F116Y, Q151M, Y181C, Y181I, M184V, M184I, Y188C, Y188L,
Y188H, G190A, G190S, L210W, T215Y, T215F, K219Q, K219E
and P225H; proteaseD30N, V32I, M46I, M46L, I47A, I47V,
G48V, I50L, I50V, I54L, I54M, Q58E, L76V, V82A, V82F, V82L,
V82S, V82T, N83D, I84V, N88S and L90M.
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Phylogenetic analysis
Sequence alignment was performed by CLUSTAL W (BioEdit
7.1.3.0 sequence alignment editor [37]). Neighbour-joining
(NJ) trees were constructed under the Kimura 2-parameter
model with the MEGA5 programme [38]. Sequences were
individually analyzed by Simplot 3.5.1 [39] and recombination
analysis was then performed by bootscanning analysis [39].
Statistical analysis
Chi-square test and Fisher’s exact test were used to compare
proportions of resistance mutations and patient’s epidemio-
logical records.
Results
A total of 197 newly HIV-1-diagnosed individuals were
studied. The average age was 37 years. In 45 cases, the pol
gene could not be successfully sequenced and were excluded
from the analysis, resulting in a total of 152 analyzed samples
(77%). Phylogenetic analyses showed predominance of
two viral subtypes: 77 (50.6%) samples were recombinants
between subtypes B and F, 70 (46.0%) were subtypes B and
5 (3.3%) were ‘‘non B-non BF’’ variants.
Twelve individuals (7.9%) were found to harbour primary
resistance mutations, 12 males and 1 female. No significant
associations were found between presence of variants with
resistance mutations and patient’s epidemiological records,
CD4 count, VL or viral subtype (Supplementary Table 1).
According to drug class, mutations associated with resistance
to NNRTI were the most prevalent, being present in nine
(5.9%) individuals. NRTI mutations and primary mutations
associated with resistance to protease inhibitors (PIs) were
both found each in two individuals (1.3%).
The most prevalent resistance mutations associated with
NNRTI were K103N and G190A. Both were present in 88.9%
(8/9) patients with primary resistance mutations for this class
of drugs and accounts for the 66.7% (8/12) of the overall
primary resistance and for 90% (9/10) of the NNRTI
resistance. Regarding PI resistance mutations, they were
found in two patients (Table 1) who shared the same
mutations profile. One of them was a 32-year-old MSM
man enrolled at the Site D, and the other was a 25-year-old
bisexual man enrolled at the Site F. Phylogenetic analysis
revealed a close relationship between both viral strains as
evidenced by the monophyletic highly supported clade
containing both sequences (bootstrap100, data not
shown). While these two sequences are closely related,
according to the phylogenetic analysis they are separated by
a genetic distance of 0.062 showing that, in spite of sharing
the same mutation profile, they are different from each other
(Supplementary Figure 1).
When we compared these results with our previous
studies, as shown in Figure 1, we observed an almost
significant increase in NNRTI resistance compared with data
collected in 20032005 (p0.052) and a significant increase
compared with data collected in 19972000 (p0.028). The
overall trend across the 10-year period was significant for
NNRTI resistance (Chi-square for trend, p0.0072) and
almost significant for overall resistance (Chi-square for trend,
p0.052).
Finally, we re-analyzed our dataset using the list of
mutations reported by the WHO guidelines [21]. Among
patients with no evidence of primary resistance based on the
IAS list, none of them presented resistance mutations based
on the WHO list. Among the 12 patients with evidence of
primary resistance based on the IAS list, 11 of them
presented resistance mutations according to the WHO
guidelines while patient ID#7 (Table 1) exhibited the
mutations K101P that is not considered by the WHO
guidelines.
Discussion
Based on our results, 7.9% (CI: 3.612.2, n152) of
individuals newly diagnosed between 2010 and 2011 in
Buenos Aires harbour major resistance mutations associated
with reduced susceptibility to ARV drugs. This figure is similar
to that observed in other developing countries [714] but
still lower than the prevalence observed in many developed
settings [1519,21].
Previously, we had reported a prevalence of 2.3% (CI: 0
5.5, n86) primary resistance in a similar population
diagnosed between 1997 and 2000 [32], and 4.2% (CI: 1.9
6.5, n284) [32] for 20032005. Comparing prevalence in
the first study with the one reported in the present study,
we observed an increase of almost four-folds (p0.028) in
10 years. When data were analyzed separately according to
drug class, we observed that the mentioned trend was driven
by the increase in NNRTI resistance mutations for which
the prevalence resulted increased from no detection of
those mutations in the first period to a prevalence of 2.1% in
20032005 and 5.9% in 20102011 (Chi-square for trend,
p0.0072). At the mutation level, K103N represents around
the 50% of NNRTI primary resistance in the last two periods
while the remaining 50% was dominated by the V108I
mutation in the previous study and by the G190A mutation
in the present study. It is important to highlight that, as
reported by June 2010, in Buenos Aires the 86.6% of patients
treated with NNRTIs were under efavirenz-based regimens
and the remaining 13.3% were under nevirapine-based
regimens [40], which are significantly impaired by K03N
mutation. Therefore, it is likely that ARV treatment constitute
indeed the population-level selective force driving persis-
tence of this mutation in our population since K103N is not a
natural polymorphism of the virus circulating in our region.
Interestingly, we found a high prevalence of G190A, not
previously reported in the region; and the absence of V108I,
found about equally often as K103N in our previous study
during 20032005.
It is important to highlight that in the present study we did
not considered any upper limit for the age at enrolment
while the 2008 WHO HIVDR guidelines, as well as the 2012
update, recommend restricting the inclusion criteria to
patients younger than 25 years in order to minimize the
proportion of chronically HIV-positive individuals and to
obtain a better estimate of transmitted resistance. Applying
that restriction to our study results in a similar estimation or
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Table 1. Epidemiological and virological characteristics of the 12 individuals harbouring resistance mutations
Resistance mutations
ID
Age
group
Risk
group Site
First HIV-positive
diagnosis
Sampling
date Clinical stage at diagnosis
Viral
subtype
CD4 count
(cells/ml) Log10 (VL)
Protease
inhibitor
Nucleoside RT
inhibitor
Non-nucleoside
RT inhibitor
1 5055 HTS A 05.27.2010 09.27.2010 Asymptomatic BF 337 4.58   K103N
2 3035 HTS B 07.16.2010 09.16.2010 Symptomatic without AIDS criteria B 132 5.87   G190A
3 3540 MSM A 12.01.2010 02.01.2011 Asymptomatic B 218 4.66  A62V**, T215D* 
4 3540 HTS C 11.01.2010 01.04.2011 AIDS BF 146 2.85   G190A
5 3035 MSM D 08.20.2010 11.05.2010 Acute retroviral syndrome BF 394 NA M46I, L76V,
V82A, I54V*
 
6 2025 HTS C 10.01.2010 10.13.2010 Asymptomatic B 301 4.53   K103N
7 3035 MSM E 11.30.2010 02.08.2011 Asymptomatic B 494 4.92   K101P**
8 3035 HTS D 02.10.2011 02.28.2011 AIDS BF 74 NA   K103N
9 2025 Bisexual F 08.17.2010 09.23.2010 Asymptomatic BF 308 NA M46I, L76V,
V82A, I54V*
 
10 3540 MSM E 12.14.2010 02.08.2011 NA B 22 4.49 T69D* D67N, K70R, M184V,
T215F, K219Q
G190A, K101E*
11 4045 NA C 05.05.2010 11.02.2010 Symptomatic without AIDS criteria B 473 4.85   K103N
12 4550 MSM E 12.14.2010 02.15.2011 Asymptomatic BF 363 5.65   G190A
*Considered resistance mutations only by the WHO guidelines. **Considered resistance mutations only by the IAS guidelines.
NAnot available, VLviral load, RT reverse transcriptase.
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resistance (7.1%) (Supplementary Table 1), in contrast to
previous studies that have found significantly different
prevalence in that age group [41]. However, the limited
sample size of patients younger than 25 limits any further
analysis.
According to our results, during the course of the past
10 years a significant increase in primary resistance to
NNRTIs has occurred. Although prevalence remains lower
than in developed settings, our study shows that accumula-
tion of ARV resistance mutations can be a significant public
health concern even in settings where the proportion of
individuals living with HIV under treatment is limited.
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